Stratec Biomedical Systems AG (SBS)

  22.50
   
  • Change Today:
     0.20
  • 52 Week High:  36.60
  • 52 Week Low:  19.64
  • Currency: Euro
  • Shares Issued: 11.94m
  • Volume: 4,434
  • Market Cap:  268.65m
Select chart: 1 week | 1 month | 1 year
 

Current

1 week

Forecasts

Year Ending Revenue ( m) Pre-tax ( m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 259.01 24.80 136.71¢ 16.5 0.2 +82% 61.17¢ 0.0%
31-Dec-26 276.56 32.21 188.67¢ 11.9 0.3 +38% 70.67¢ 0.0%
31-Dec-27 296.50 37.81 222.43¢ 10.1 0.6 +18% 77.14¢ 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

Forecast Ratios

Year Ending Revenue/Share Price/Revenue per Share
31-Dec-25  21.69 1.04
31-Dec-26  23.16 0.97
31-Dec-27  24.83 0.91

Trends & Recommendations

  Current 1 week ago 1 month ago 3 months ago 6 months ago 1 year ago
Revenue ( m)
31-Dec-2026 277 n/a n/a n/a n/a 295
31-Dec-2027 296 n/a n/a n/a n/a n/a
 
Earnings
31-Dec-2026 188.67¢ n/a n/a n/a n/a 229.40¢
31-Dec-2027 222.43¢ n/a n/a n/a n/a n/a
 
Dividend
31-Dec-2026 70.67¢ n/a n/a n/a n/a 94.78¢
31-Dec-2027 77.14¢ n/a n/a n/a n/a n/a
 
Recommendations
Strong Buy 4 4 4 0 0 2
Buy 2 2 2 0 0 1
Neutral 3 3 3 0 0 6
Sell 0 0 0 0 0 0
Strong Sell 1 1 1 0 0 1
No. of Brokers 10 10 10 0 0 10
 
Average Rec 7.00 7.00 7.00 n/a n/a 5.75

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Broker estimates sourced from FactSet Estimates +44 (0) 20 3009 7000. FactSet Estimates calculate consensus using only those estimates changed or actively validated within the last 75 days.

Note 3: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 4: Forecast figures based on normalised accounts.

 

SBS Market Data

Currency Euro
Share Price   22.50
Change Today   0.20
% Change 0.90 %
52 Week High  36.60
52 Week Low  19.64
Volume 4,434
Shares Issued 11.94m
Market Cap  268.65m

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 3
Sell 0
Strong Sell 1
Total 10
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Top of Page